We are live on ! Find out more
GA

Geneva Advisors Portfolio holdings

AUM $5.81B
1-Year Est. Return 23.71%
This Fund
S&P 500
This Quarter Est. Return
+1.09%
1 Year Est. Return
+23.71%
3 Year Est. Return
+53.12%
5 Year Est. Return
10 Year Est. Return
AUM
$5.6B
AUM Growth
+$69.6M
Cap. Flow
+$51.5M
Cap. Flow %
0.92%
Top 10 Hldgs %
21.06%
Holding
781
New
66
Increased
297
Reduced
239
Closed
62

Top Sells

Rank Stock Value
1
PII icon
Polaris
PII
+$36M
2
TROW icon
T. Rowe Price
TROW
+$31.5M
3
ELV icon
Elevance Health
ELV
+$27.8M
4
ITC
ITC HOLDINGS CORP
ITC
+$26.5M
5
AMAT icon
Applied Materials
AMAT
+$24.6M

Sector Composition

Rank Sector Weight
1 Healthcare 19.08%
2 Financials 18.2%
3 Consumer Discretionary 11.88%
4 Technology 11.08%
5 Industrials 10.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MHFI
51
DELISTED
MCGRAW-HILL FINANCIAL INC COM
MHFI
$37.6M 0.67%
374,104
+2,451
+0.7% +$256K
ARMH
52
DELISTED
ARM HOLDINGS PLC ADS
ARMH
$37.5M 0.67%
761,310
+10,023
+1% +$521K
GILD icon
53
Gilead Sciences
GILD
$185B
$37.1M 0.66%
316,596
+20,090
+7% +$2.2M
APAM icon
54
Artisan Partners
APAM
$3.09B
$36.7M 0.66%
789,482
-30,873
-4% -$1.41M
LYB icon
55
LyondellBasell Industries
LYB
$20.4B
$36.1M 0.64%
348,575
+336,665
+2,827% +$33.9M
AGN
56
DELISTED
Allergan plc
AGN
$36M 0.64%
118,708
+1,606
+1% +$479K
CPAY icon
57
Corpay
CPAY
$26.5B
$35M 0.63%
224,374
-716
-0.3% -$112K
CAH icon
58
Cardinal Health
CAH
$54.7B
$32.9M 0.59%
392,931
+4,414
+1% +$390K
BMY icon
59
Bristol-Myers Squibb
BMY
$137B
$32.4M 0.58%
486,881
+10,961
+2% +$722K
EW icon
60
Edwards Lifesciences
EW
$51.8B
$31.9M 0.57%
1,342,410
+15,738
+1% +$355K
ETP
61
DELISTED
Energy Transfer Partners, L.P.
ETP
$31.2M 0.56%
819,926
-5,566
-0.7% -$227K
IDXX icon
62
Idexx Laboratories
IDXX
$42.9B
$30.8M 0.55%
480,778
-1,992
-0.4% -$138K
CF icon
63
CF Industries
CF
$19B
$29.4M 0.53%
457,555
-255,460
-36% -$15.6M
CVS icon
64
CVS Health
CVS
$119B
$28.8M 0.51%
274,679
+2,871
+1% +$293K
UPS icon
65
United Parcel Service
UPS
$89.9B
$27.1M 0.48%
279,859
-2,044
-0.7% -$203K
NXPI icon
66
NXP Semiconductors
NXPI
$57B
$25.8M 0.46%
262,659
+13,725
+6% +$1.41M
AX icon
67
Axos Financial
AX
$5.52B
$25M 0.45%
944,976
+320,184
+51% +$7.61M
SHW icon
68
Sherwin-Williams
SHW
$83.8B
$24.5M 0.44%
267,237
+10,191
+4% +$966K
AYI icon
69
Acuity Brands
AYI
$10.2B
$24.1M 0.43%
134,146
+5,002
+4% +$878K
BIP icon
70
Brookfield Infrastructure Partners
BIP
$17.9B
$23.4M 0.42%
1,319,331
-8,724
-0.7% -$154K
CBRE icon
71
CBRE Group
CBRE
$42.6B
$22.5M 0.4%
608,068
+7,379
+1% +$280K
CTSH icon
72
Cognizant
CTSH
$28.7B
$22.3M 0.4%
364,902
-977
-0.3% -$61.3K
NOW icon
73
ServiceNow
NOW
$143B
$21.6M 0.39%
1,455,445
+60,155
+4% +$928K
POT
74
DELISTED
Potash Corp Of Saskatchewan
POT
$21.6M 0.39%
698,035
-82,999
-11% -$2.66M
TRIP icon
75
TripAdvisor
TRIP
$1.15B
$20.6M 0.37%
236,200
-10,338
-4% -$841K

Similar funds

Geneva Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Geneva Advisors held 781 positions worth $5.6B, up 1.3% from $5.53B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Geneva Advisors's Q2 2015 filing shows 66 new, 297 increased, 239 reduced and 62 closed positions. Its largest new stake was LinkedIn Corporation: 75,249 shares worth $15.5M. The largest sale was Polaris, an estimated $36M.

By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 19% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Geneva Advisors's largest Q2 2015 buy was LinkedIn Corporation: 75,249 shares worth $15.5M.
  • Geneva Advisors added most to TD Ameritrade Holding Corp in Q2 2015, an estimated $41.7M increase.
  • Geneva Advisors's biggest Q2 2015 reduction was Polaris, cutting an estimated $36M.
  • Geneva Advisors fully exited Applied Materials in Q2 2015, selling an estimated $24.6M.
  • Geneva Advisors's ten largest holdings make up 21% of its $5.6B portfolio in Q2 2015.
  • Geneva Advisors opened 66 new positions and closed 62 in Q2 2015.
  • Geneva Advisors's portfolio value rose 1.3% quarter-over-quarter to $5.6B.

Based on Geneva Advisors's 13F filing for Q2 2015, filed 3 Aug 2015.